Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

J&J Trims Annual Profit Forecast Due To Vaccine Performance – $JNJ DIA

By John F. Heerdink, Jr.

Johnson & Johnson (JNJ) released quarterly earnings, refusing to provide a forecast for sales of its COVID-19 vaccine, as vaccine hesitancy in low-income countries and low demand in higher-income nations, lead to a surplus. J&J also cut both ends of its full-year profit forecast by 25 cents and now expects to earn $10.15 to $10.35 per share.  The J&J shot has been linked to rare, but potentially deadly blood clots, manufacturing issues, and concerns about efficacy. It accounts for about 3% of all doses administered in the United States, and roughly 2% of doses in Europe.

The vaccine reported $457 million in the first quarter. The company expects its medical devices unit to recover this year after pandemic delays in non-urgent surgeries hurt sales last year, and it expects above-market growth in its large pharmaceuticals business this year.

The company reported pharmaceutical sales of $12.87 billion, shy of forecasts for $13.6 billion, due in part to low vaccine sales. Excluding items, J&J earned $2.67 per share for the quarter, beating analysts’ expectations by 11 cents.

Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare-focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.

If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus. 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.

(Read Original Story: J&J suspends COVID vaccine sales forecast on low demand, supply glut in Reuters)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us